Review
Medicine, General & Internal
Stephen A. Klassen, Jonathon W. Senefeld, Katherine A. Senese, Patrick W. Johnson, Chad C. Wiggins, Sarah E. Baker, Noud van Helmond, Katelyn A. Bruno, Liise-anne Pirofski, Shmuel Shoham, Brenda J. Grossman, Jeffrey P. Henderson, R. Scott Wright, DeLisa Fairweather, Nigel S. Paneth, Rickey E. Carter, Arturo Casadevall, Michael J. Joyner
Summary: Global evidence suggests that convalescent plasma can improve COVID-19 patient survival, particularly when transfused early in the disease course. Randomized controlled trials have shown limited or no benefit when transfused later in the disease course. Convalescent plasma also contributes to improved symptomatology and viral clearance, and has a similar safety profile as standard plasma.
FRONTIERS IN MEDICINE
(2021)
Review
Immunology
Anselm Jorda, Manuel Kussmann, Nebu Kolenchery, Jolanta M. Siller-Matula, Markus Zeitlinger, Bernd Jilma, Georg Gelbenegger
Summary: The efficacy of convalescent plasma treatment for Covid-19 remains uncertain. A systematic review and meta-analysis of randomized controlled trials found that treatment with convalescent plasma did not result in lower all-cause mortality or improved disease progression in patients with Covid-19, regardless of disease severity and baseline antibody status.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Jun Wu, Boyun Liang, Cunrong Chen, Hua Wang, Yaohui Fang, Shu Shen, Xiaoli Yang, Baoju Wang, Liangkai Chen, Qi Chen, Yang Wu, Jia Liu, Xuecheng Yang, Wei Li, Bin Zhu, Wenqing Zhou, Huan Wang, Sumeng Li, Sihong Lu, Di Liu, Huadong Li, Adalbert Krawczyk, Mengji Lu, Dongliang Yang, Fei Deng, Ulf Dittmer, Mirko Trilling, Xin Zheng
Summary: The study quantified IgM and IgG antibodies recognizing SARS-CoV-2 in 349 symptomatic COVID-19 patients over 6 months, showing that IgM levels dropped after 3 months while IgG responses contracted but remained high at 6 months.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Pavlo Gilchuk, Isaac Thomsen, Sandra Yoder, Eric Brady, James D. Chappell, Laura J. Stevens, Mark R. Denison, Rachel E. Sutton, Rita E. Chen, Laura A. VanBlargan, Naveenchandra Suryadevara, Seth J. Zost, Jonathan Schmitz, Jill M. Pulley, Michael S. Diamond, Jillian P. Rhoads, Gordon R. Bernard, Wesley H. Self, Todd W. Rice, Allison P. Wheeler, James E. Crowe, Robert H. Carnahan
Summary: The COVID-19 pandemic has highlighted the urgent need for rapid evaluation of neutralizing antibody responses and the development of antibody-based treatments. The currently approved serological tests do not measure antibody-mediated viral neutralization, and there is a need for standardized quantitative neutralization assays. This study presents a high-throughput two-step profiling approach for identifying neutralizing convalescent plasma. Additionally, the researchers introduce a neutralizing antibody standard reagent to calibrate antibody neutralizing activity in convalescent plasma.
Article
Multidisciplinary Sciences
Paola de Candia, Francesco Prattichizzo, Silvia Garavelli, Rosalba La Grotta, Annunziata De Rosa, Agostina Pontarelli, Roberto Parrella, Antonio Ceriello, Giuseppe Matarese
Summary: The study results indicate that the use of convalescent plasma in early stages of COVID-19 can significantly reduce mortality, but its effectiveness is not significant in severe or critical conditions. Additionally, plasma with high antibody titers does not increase the benefit in reducing mortality.
Review
Hematology
Aaron A. R. Tobian, Claudia S. Cohn, Beth H. Shaz
Summary: COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19 that works through the mediation of antibodies and is primarily effective for elderly outpatients in the early stages of the disease. However, it is not effective for hospitalized patients with moderate to severe disease. Collection of CCP should be as close as possible to the time and location of the patient.
Review
Medicine, General & Internal
Vanessa Piechotta, Claire Iannizzi, Khai Li Chai, Sarah J. Valk, Catherine Kimber, Elena Dorando, Ina Monsef, Erica M. Wood, Abigail A. Lamikanra, David J. Roberts, Zoe McQuilten, Cynthia So-Osman, Lise J. Estcourt, Nicole Skoetz
Summary: Convalescent plasma and hyperimmune immunoglobulin are being investigated as potential therapies for COVID-19, with a living systematic review approach being used to assess their effectiveness and safety. The current evidence suggests that convalescent plasma does not reduce all-cause mortality or significantly improve clinical outcomes for individuals with moderate to severe disease, but its impact on other outcomes remains uncertain. Further ongoing studies are needed to determine the full potential of these interventions.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Immunology
Hannah A. D. King, Vincent Dussupt, Letzibeth Mendez-Rivera, Bonnie M. M. Slike, Ursula Tran, Nathan D. D. Jackson, Erica Barkei, Michelle Zemil, Emily Tourtellott-Fogt, Caitlin H. H. Kuklis, Sandrine Soman, Aslaa Ahmed, Maciel Porto, Christopher Kitajewski, Brittany Spence, Dalia Benetiene, Lindsay Wieczorek, Swagata Kar, Gregory Gromowski, Victoria R. R. Polonis, Shelly J. J. Krebs, Kayvon Modjarrad, Diane L. L. Bolton
Summary: This study investigates the protective effects of convalescent immunoglobulins against SARS-CoV-2 in a Syrian golden hamster model. It shows that IgM has higher neutralization potency than IgG, but fails to protect hamsters from disease. IgG infusion, on the other hand, effectively prevents disease in a dose-dependent manner, with detectable neutralizing titers correlating with protection.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Critical Care Medicine
Wesley H. Self, Allison P. Wheeler, Thomas G. Stewart, Harry Schrager, Jason Mallada, Christopher B. Thomas, Vince D. Cataldo, Hollis R. O'Neal, Nathan Shapiro, Conor Higgins, Adit A. Ginde, Lakshmi Chauhan, Nicholas J. Johnson, Daniel J. Henning, Stuti J. Jaiswal, Manoj J. Mammen, Estelle S. Harris, Sonal R. Pannu, Maryrose Laguio-Vila, Wissam El Atrouni, Marjolein de Wit, Daanish Hoda, Claudia S. Cohn, Carla McWilliams, Carl Shanholtz, Alan E. Jones, Jay S. Raval, Simon Mucha, Tina S. Ipe, Xian Qiao, Stephen J. Schrantz, Aarthi Shenoy, Richard D. Fremont, Eric J. Brady, Robert H. Carnahan, James D. Chappell, James E. Crowe, Mark R. Denison, Pavlo Gilchuk, Laura J. Stevens, Rachel E. Sutton, Isaac Thomsen, Sandra M. Yoder, Amanda J. Bistran-Hall, Jonathan D. Casey, Christopher J. Lindsell, Li Wang, Jill M. Pulley, Jillian P. Rhoads, Gordon R. Bernard, Todd W. Rice
Summary: This study found that convalescent plasma treatment did not improve clinical outcomes in hospitalized COVID-19 patients, including those without anti-SARS-CoV-2 antibodies.
Article
Respiratory System
Timothy Devos, Quentin Van Thillo, Veerle Compernolle, Tome Najdovski, Marta Romano, Nicolas Dauby, Laurent Jadot, Mathias Leys, Evelyne Maillart, Sarah Loof, Lucie Seyler, Martial Moonen, Michel Moutschen, Niels Van Regenmortel, Kevin K. Arien, Cyril Barbezange, Albrecht Betrains, Mutien Garigliany, Matthias M. Engelen, Iwein Gyselinck, Piet Maes, Alexander Schauwvlieghe, Laurens Liesenborghs, Ann Belmans, Peter Verhamme, Geert Meyfroidt
Summary: Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Letter
Medicine, General & Internal
David Fisher, Stephen Malnick
Summary: The researchers administered convalescent plasma to high-risk outpatients within 1 week after the onset of symptoms of Covid-19, which differs from previous studies with shorter time frames.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Yunbao Pan, Xianghu Jiang, Liu Yang, Liangjun Chen, Xiaojiao Zeng, Guohong Liu, Yueting Tang, Chungen Qian, Xinming Wang, Fangming Cheng, Jun Lin, Xinghuan Wang, Yirong Li
Summary: Our study on COVID-19 convalescent individuals showed that the survival of neutralizing antibodies is significantly affected by IL-2, IL-8, and IFN-gamma responses, while the activation of T cells and NK cells stimulated by antigen peptide pools is correlated with the presence of neutralizing antibodies. These findings provide insights into protective immunity against SARS-CoV-2, the pathogenesis of COVID-19, and the development of an effective vaccine.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Virology
Laura Thuemmler, Monika Lindemann, Peter A. Horn, Veronika Lenz, Margarethe Konik, Anja Gaeckler, Kristina Boss, Fotis Theodoropoulos, Vasiliki Besa, Christian Taube, Thorsten Brenner, Oliver Witzke, Adalbert Krawczyk, Hana Rohn
Summary: Vulnerable patients such as immunosuppressed or elderly patients are at high risk for severe COVID-19 and can be effectively protected by immunotherapy with SARS-CoV-2 specific monoclonal antibodies (mAb) or convalescent plasma. Our study showed that mAb treatment is highly effective in preventing severe courses of SARS-CoV-2 infection, while convalescent plasma treatment improved overall survival of high-risk COVID-19 patients.
Review
Immunology
Ying Wang, Pengfei Huo, Rulin Dai, Xin Lv, Shaofei Yuan, Yang Zhang, Yiming Guo, Rui Li, Qian Yu, Kun Zhu
Summary: The effectiveness of convalescent plasma (CP) immunotherapy for COVID-19 in reducing mortality and improving clinical symptoms remains controversial based on current evidence, but it may have a positive impact on treating COVID-19 patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Virology
Soumya Sarkar, Kapil D. Soni, Puneet Khanna
Summary: Convalescent plasma therapy (CPT) may help reduce mortality, accelerate viral clearance, and improve clinical conditions in COVID-19 patients, but the existing evidence is of low quality. Further randomized controlled trials are needed to confirm the safety and effectiveness of CPT.
JOURNAL OF MEDICAL VIROLOGY
(2021)
